REFERENCES
1. Krivosheeva E.N., Panchenko E.P., Kropacheva E.S., Dobrovolsky A.B., Titaeva E.V., Mironov V.M., et al. Prediction-Determining Outcomes and Their Predictors in Atrial Fibrillation Patients Receiving Multicomponent Antithrombotic Therapy in Real Clinical Practice. Kardiologiya [Cardiology]. 2020; 60 (8): 33–45. (in Russian)
2. van Rein N., Heide-Jørgensen U., Lijfering W.M., Dekkers O.M., Sørensen H.T., Cannegieter S.C. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy: Results From a Nationwide Danish Cohort Study. Circulation. 2019; 139 (6): 775–86. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.036248
3. Sycheva N.A., Koroleva L. Yu., Nosov V.P., Volkova A.T., Kisel A.M., Kovaleva G.V., et al. Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study. Kardiologiya [Cardiology]. 2020; 60 (7): 53–63. (in Russian)
4. Golitsyn S.P., Panchenko E.P., Kropacheva E.S., Layovich L. Yu., Maikov E.B., Mironov N. Yu., et al. Eurasian clinical recommendations on diagnosis and treatment of atrial fibrillation. Eurasian heart journal. 2019; 4: 4–85. (in Russian)
5. Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018; 39 (3): 213–60. DOI: https://doi.org/10.1093/eurheartj/ehx419
6. Neumann F.-J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019; 40 (2): 87–165. DOI: https://doi.org/10.1093/eurheartj/ehy394
7. Byrne R.A., Rossello X., Coughlan J.J., et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023; 44 (38): 3720–826. DOI: https://doi.org/10.1093/eurheartj/ehad191
8. Daher J., Da Costa A., Hilaire C., et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig. 2020; 40 (4): 343–53. DOI: https://doi.org/10.1007/s40261-020-00898-3
9. Durrer-Ariyakuddy K., Moccetti F., Stämpfli S. Direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus – insights from multicenter registry. Cardiovasc Med. 2019; 22: 27. DOI: https://doi.org/10.4414/cvm.2019.02052
10. Gama F., Freitas P., Trabulo M., et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J. 2019; 40 (Suppl_1): ehz747.0118. DOI: https://doi.org/10.1093/eurheartj/ehz747.0118
11. Hansen M.L., Sørensen R., Clausen M.T., Fog-Petersen M.L., Raunsø J., et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Archives of Internal Medicine. 2010; 170 (16): 1433–41. DOI: https://doi.org/10.1001/archinternmed.2010.271
12. Reynolds M.W., Fahrbach K., Hauch O., Wygant G., Estok R., Cella C., et al. Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation. Chest. 2004; 126 (6): 1938–45. DOI: https://doi.org/10.1378/chest.126.6.1938
13. Sheikh A.B., Shah I., Sagheer S., Javed N., Minhas A.M.K., Lopez E.D., Parikh C., Shekhar R. Hemopericardium in the Setting of Direct Oral Anticoagulant Use: An Updated Systematic Review. Cardiovasc Revasc Med. 2022; 39: 73–83. DOI: https://doi.org/10.1016/j.carrev.2021.09.010 Epub 2021 Sep 29. PMID: 34607787.
14. Olagunju A., Khatib M., Palermo-Alvarado F. A Possible Drug-Drug Interaction Between Eliquis and Amiodarone Resulting in Hemopericardium. Cureus. 2021; 13 (2): e13486. DOI: https://doi.org/10.7759/cureus.13486 PMID: 33777573; PMCID: PMC 7990001.